Cortex Pharmaceuticals Inc.:

The Irvine developer of drug therapies for neurological and psychiatric disorders posted a net loss of $658,000, or 4 cents a share, for the third fiscal quarter, contrasted with net income of $979,000, or 6 cents a share, for the corresponding period a year earlier. Revenue fell to $852,000 from $2.5 million.

The company also said it has failed to qualify for listing on the Nasdaq market system because the stock has been trading below the required minimum price of $4 a share. Cortex applied for Nasdaq listing late in March. The over-the-counter stock traded as high as $8.13 a share on March 6 but has been trading below $4 since April 10. The shares closed Friday at $3, off 6 cents.